精准肿瘤学时代的生物标志物
Biomarkers in the Era of Precision Oncology.
作者信息
Baxevanis Constantin N
机构信息
Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 11522 Athens, Greece.
出版信息
Cancers (Basel). 2023 Mar 15;15(6):1782. doi: 10.3390/cancers15061782.
Abstract
Cancer heterogeneity provides a formidable obstacle to optimizing clinical protocols to achieve durable clinical responses [...].
摘要
癌症异质性为优化临床方案以实现持久临床反应带来了巨大障碍[...]。
相似文献
1
Biomarkers in the Era of Precision Oncology.精准肿瘤学时代的生物标志物
Cancers (Basel). 2023 Mar 15;15(6):1782. doi: 10.3390/cancers15061782.
2
Implementing precision cancer medicine in the genomic era.在基因组时代实施精准肿瘤医学。
Semin Cancer Biol. 2019 Apr;55:16-27. doi: 10.1016/j.semcancer.2018.05.009. Epub 2018 May 30.
3
Clinical trials in the era of personalized oncology.个体化肿瘤学时代的临床试验。
CA Cancer J Clin. 2011 Nov-Dec;61(6):365-81. doi: 10.3322/caac.20135. Epub 2011 Oct 27.
4
Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems.精准肿瘤学时代的癌症生物标志物：满足患者和医疗体系的需求。
Semin Cancer Biol. 2022 Sep;84:293-301. doi: 10.1016/j.semcancer.2021.08.002. Epub 2021 Aug 10.
5
Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.泛组学时代用于精准肿瘤学的基于个性化网络的药物重新定位基础设施。
Brief Bioinform. 2017 Jul 1;18(4):682-697. doi: 10.1093/bib/bbw051.
6
Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine.精准医疗时代的胰腺癌免疫肿瘤学
Indian J Surg Oncol. 2021 Apr;12(Suppl 1):118-127. doi: 10.1007/s13193-020-01192-6. Epub 2020 Aug 25.
7
Drug Repurposing for Cancer Therapy in the Era of Precision Medicine.精准医学时代的癌症治疗药物再利用
Curr Mol Pharmacol. 2022;15(7):895-903. doi: 10.2174/1874467215666220214104530.
8
Challenges, opportunities, and innovative statistical designs for precision oncology trials.精准肿瘤学试验的挑战、机遇与创新统计设计
Ann Transl Med. 2022 Sep;10(18):1038. doi: 10.21037/atm-22-356.
9
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls.将下一代测序技术整合到临床肿瘤学中：策略、前景与陷阱。
ESMO Open. 2016 Nov 18;1(5):e000094. doi: 10.1136/esmoopen-2016-000094. eCollection 2016.
10
Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations.小细胞肺癌的精准治疗：当前进展、新挑战与期望
Biochim Biophys Acta Rev Cancer. 2022 Sep;1877(5):188798. doi: 10.1016/j.bbcan.2022.188798. Epub 2022 Sep 10.
引用本文的文献
1
Precision Medicine for Cancer and Health Equity in Latin America: Generating Understanding for Policy and Health System Shaping.拉丁美洲癌症精准医学与健康公平：增进对政策制定和卫生系统塑造的理解
Int J Environ Res Public Health. 2025 Aug 5;22(8):1220. doi: 10.3390/ijerph22081220.
2
Immunotherapy in Non-Small-Cell Lung Cancer: A Modified Delphi Survey Consensus on First Line Treatment, Special Populations and Rechallenge.非小细胞肺癌的免疫治疗：关于一线治疗、特殊人群和再挑战的改良德尔菲调查共识
Biomedicines. 2024 Nov 29;12(12):2742. doi: 10.3390/biomedicines12122742.
3
Contemporary Update on Clinical and Experimental Prostate Cancer Biomarkers: A Multi-Omics-Focused Approach to Detection and Risk Stratification.前列腺癌临床与实验生物标志物的当代进展：一种聚焦多组学的检测与风险分层方法
Biology (Basel). 2024 Sep 25;13(10):762. doi: 10.3390/biology13100762.
本文引用的文献
1
Quantitative Evaluation of Stem-like Markers of Human Glioblastoma Using Single-Cell RNA Sequencing Datasets.使用单细胞RNA测序数据集对人胶质母细胞瘤的干细胞样标志物进行定量评估
Cancers (Basel). 2023 Mar 2;15(5):1557. doi: 10.3390/cancers15051557.
2
The Receptor for Advanced Glycation Endproducts (RAGE) and Its Ligands S100A8/A9 and High Mobility Group Box Protein 1 (HMGB1) Are Key Regulators of Myeloid-Derived Suppressor Cells.晚期糖基化终末产物受体（RAGE）及其配体S100A8/A9和高迁移率族蛋白1（HMGB1）是髓源性抑制细胞的关键调节因子。
Cancers (Basel). 2023 Feb 6;15(4):1026. doi: 10.3390/cancers15041026.
3
Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis.卵巢癌患者综合基因组分析的实施：一项回顾性分析
Cancers (Basel). 2022 Dec 29;15(1):218. doi: 10.3390/cancers15010218.
4
Association between Intratumoral CD8+ T Cells with FoxP3+ and CD163+ Cells: A Potential Immune Intrinsic Negative Feedback Mechanism for Acquired Immune Resistance.肿瘤内CD8+ T细胞与FoxP3+和CD163+细胞之间的关联：获得性免疫抗性的一种潜在免疫内在负反馈机制。
Cancers (Basel). 2022 Dec 15;14(24):6208. doi: 10.3390/cancers14246208.
5
Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.肿瘤突变负荷与突变谱之间的相互作用及其对总生存期的影响：一项接受免疫检查点抑制剂治疗的转移性患者的初步研究
Cancers (Basel). 2022 Nov 4;14(21):5433. doi: 10.3390/cancers14215433.
6
Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma.综合生物标志物分析揭示L1CAM作为无特定分子特征的高危子宫内膜癌的潜在分层标志物。
Cancers (Basel). 2022 Nov 3;14(21):5429. doi: 10.3390/cancers14215429.
7
Apelin, a Circulating Biomarker in Cancer Evaluation: A Systematic Review.Apelin，一种用于癌症评估的循环生物标志物：一项系统综述。
Cancers (Basel). 2022 Sep 25;14(19):4656. doi: 10.3390/cancers14194656.
8
Increased Density of Growth Differentiation Factor-15+ Immunoreactive M1/M2 Macrophages in Prostate Cancer of Different Gleason Scores Compared with Benign Prostate Hyperplasia.与良性前列腺增生相比，不同Gleason评分的前列腺癌中生长分化因子-15+免疫反应性M1/M2巨噬细胞密度增加。
Cancers (Basel). 2022 Sep 22;14(19):4591. doi: 10.3390/cancers14194591.
9
T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker.肿瘤放疗中的T细胞受体库：作为放疗生物标志物的新兴前沿领域。
Cancers (Basel). 2022 May 27;14(11):2674. doi: 10.3390/cancers14112674.
10
Emerging Biomarkers for Immunotherapy in Glioblastoma.胶质母细胞瘤免疫治疗的新兴生物标志物
Cancers (Basel). 2022 Apr 12;14(8):1940. doi: 10.3390/cancers14081940.
Zotero 插件